Welcome to our dedicated page for Inmode Ltd. news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode Ltd. stock.
InMode Ltd. (INMD) delivers innovative radiofrequency-based solutions for minimally invasive aesthetic treatments. This news hub provides investors and medical professionals with essential updates on the company's strategic developments, technological advancements, and market leadership in medical aesthetics.
Access real-time announcements including quarterly earnings, product launch details, regulatory milestones, and partnership agreements. Our curated collection features press releases covering facial/body contouring innovations, clinical study results, and intellectual property developments central to INMD's growth strategy.
Key updates include FDA-cleared device announcements, global expansion initiatives, and R&D breakthroughs in RF energy applications. Bookmark this page for verified information on corporate governance changes, manufacturing updates, and industry conference participation directly from InMode's communications team.
InMode (NASDAQ: INMD) has announced an additional FDA 510(k) clearance for its Morpheus8 technology, making it the first and only fractional radiofrequency (FRF) microneedling technology cleared for soft tissue contraction. This expands Morpheus8's existing FDA clearance, enhancing its versatility for physicians and patients.
Alongside this clearance, InMode is launching the new IgniteRF and OptimasMAX platforms, which include the Morpheus8 family of handpieces. These platforms support 14 technologies, offering a comprehensive solution for various skin treatments.
Morpheus8 has gained significant global brand awareness, with over 2.5 million procedures performed worldwide and an average of 8.2 treatments performed every minute. The technology's popularity has made it a trusted and requested procedure among consumers and celebrities alike.
InMode (Nasdaq: INMD), a global leader in medical technologies, announced it will release Q2 2024 financial results on August 1, 2024, before the market opens.
Preliminary results show anticipated Q2 revenue of $86.2M-$86.3M, with pro-forma revenue (including pre-orders) expected to be $102.4M-$102.5M. Non-GAAP gross margin is estimated at 80%-81%, while pro-forma Non-GAAP gross margin should be 82%-83%.
Full-year 2024 revenue guidance has been adjusted to $430M-$440M from a previous $485M-$495M forecast, reflecting macro-economic impacts and transitional effects due to new platform introductions.
A conference call to discuss the results will be held on August 1, 2024, at 8:30 a.m. Eastern Time.
InMode (Nasdaq: INMD) announced that CFO Yair Malca and CMO Spero Theodorou will present at the Jefferies Healthcare Conference in New York on June 5, 2024. The presentation, moderated by Matt Taylor, will occur at 7:30 am ET, with a live webcast available. Additionally, InMode will conduct one-on-one investor meetings on the same day. Interested parties should contact their Jefferies representative to schedule a meeting.
InMode partners with P1 Offshore Racing to sponsor female driver Victoria Rand, marking a groundbreaking move in motorsports. Victoria, with a racing background, joins the Morpheus8 Offshore Race Team to compete alongside champion Johnny Tomlinson. The partnership highlights InMode's commitment to empowering women and pushing the boundaries of aesthetics.
InMode reported first quarter 2024 financial results, with a revenue of $80.3M representing a 24% YoY decrease. The company also announced a share repurchase program and appointed a new Chairman of the Board of Directors. Pro-forma revenue, including new platform pre-orders, was $96M. Quarterly revenues from consumables and service increased by 13%. GAAP net income was $23.7M, non-GAAP net income was $27.7M, and pro-forma non-GAAP net income was $38.8M. The company has a total cash position of $770.5M as of March 31, 2024.
FAQ
What is the current stock price of Inmode Ltd. (INMD)?
What is the market cap of Inmode Ltd. (INMD)?
